No connection

Search Results

GDTC vs NXL

GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%
NXL
Nexalin Technology, Inc.
BEARISH
Price
$0.51
Market Cap
$10.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
GDTC
--
NXL
--
Forward P/E
GDTC
-6.67
NXL
-1.64
P/B Ratio
GDTC
2.31
NXL
2.61
P/S Ratio
GDTC
13.74
NXL
34.73
EV/EBITDA
GDTC
-2.73
NXL
-0.81

Profitability

Gross Margin
GDTC
89.57%
NXL
79.65%
Operating Margin
GDTC
-535.25%
NXL
-1403.86%
Profit Margin
GDTC
0.0%
NXL
0.0%
ROE
GDTC
-50.28%
NXL
-221.5%
ROA
GDTC
-29.31%
NXL
-118.41%

Growth

Revenue Growth
GDTC
46.9%
NXL
532.5%
Earnings Growth
GDTC
--
NXL
--

Financial Health

Debt/Equity
GDTC
0.07
NXL
--
Current Ratio
GDTC
5.17
NXL
4.84
Quick Ratio
GDTC
3.14
NXL
4.29

Dividends

Dividend Yield
GDTC
--
NXL
--
Payout Ratio
GDTC
0.0%
NXL
0.0%

AI Verdict

GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage
NXL BEARISH

NXL exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive year-over-year revenue growth of 532.50%, this is completely offset by a catastrophic operating margin of -1403.86% and negative ROE of -221.50%. The stock is currently trading at an exorbitant Price/Sales ratio of 34.73, which is unsustainable given the lack of profitability. Despite a recent short-term price bounce and a single analyst's 'buy' rating, the underlying deterministic data suggests a high risk of capital impairment.

Strengths
Exceptional YoY revenue growth (532.50%)
Strong gross margins (79.65%) indicating product value
Healthy short-term liquidity (Current Ratio 4.84)
Risks
Extreme operational inefficiency (Operating Margin -1403.86%)
Critical financial health failure (Piotroski F-Score 1/9)
Severe valuation disconnect (P/S Ratio 34.73)

Compare Another Pair

GDTC vs NXL: Head-to-Head Comparison

This page compares CytoMed Therapeutics Limited (GDTC) and Nexalin Technology, Inc. (NXL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile